Daily Bulletin

Men's Weekly

.

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
  • Phase 2 study of PVX108 to commence in United States and Australia
  • Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board

MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...

Read more: Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation...

Business News

Boost Your Career with Industry-Recognised Training Courses at Safety Australia Training

When it comes to workplace safety and professional development, Safety Australia Training stands out as one of the leading Registered Training Organisations (RTOs) in Australia. Whether you’re startin...

Daily Bulletin - avatar Daily Bulletin

Digital Marketing Agency in Sydney: Empowering Businesses with Smart Online Growth Strategies

Sydney’s business scene is fast-paced, diverse, and incredibly competitive. In such a dynamic environment, having a strong online presence is no longer optional — it’s essential. A digital marketing...

Daily Bulletin - avatar Daily Bulletin

Why Your Business Might Already Be a Cybercrime Target Without Knowing It

Cybercrime isn’t just something that happens to banks or large technology companies. It can happen to any business, even those that seem too small to matter. When a hacker sees an easy target, they ta...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business